KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Depreciation and Depletion (2016 - 2025)

BeOne Medicines (ONC) has disclosed Depreciation and Depletion for 11 consecutive years, with $34.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation and Depletion fell 29.83% to $34.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $131.6 million, a 21.16% decrease, with the full-year FY2025 number at $131.6 million, down 21.16% from a year prior.
  • Depreciation and Depletion was $34.4 million for Q4 2025 at BeOne Medicines, down from $35.7 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $70.0 million in Q3 2024 to a low of $9.4 million in Q1 2021.
  • A 5-year average of $24.3 million and a median of $20.1 million in 2023 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: soared 263.93% in 2024, then crashed 48.98% in 2025.
  • BeOne Medicines' Depreciation and Depletion stood at $12.3 million in 2021, then surged by 38.57% to $17.0 million in 2022, then increased by 22.38% to $20.9 million in 2023, then skyrocketed by 135.1% to $49.0 million in 2024, then dropped by 29.83% to $34.4 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Depreciation and Depletion are $34.4 million (Q4 2025), $35.7 million (Q3 2025), and $29.9 million (Q2 2025).